Blue Fin Capital’s VanEck Biotech ETF BBH Stock Holding History

Blue Fin Capital’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$314K	Hold	1,544	–	–	0.05%	138
2026 Q1	$290K	Hold	1,544	–	–	0.05%	136
2025 Q4	$292K	Sell	1,544 -26	-2%	-$4.81K	0.05%	136
2025 Q3	$260K	Hold	1,570	–	–	0.04%	135
2025 Q2	$241K	Hold	1,570	–	–	0.04%	137
2025 Q1	$247K	Hold	1,570	–	–	0.05%	127
2024 Q4	$246K	Sell	1,570 -53	-3%	-$8.92K	0.05%	126
2024 Q3	$288K	Hold	1,623	–	–	0.05%	125
2024 Q2	$273K	Sell	1,623 -24	-1%	-$3.93K	0.05%	130
2024 Q1	$274K	Sell	1,647 -138	-8%	-$22.9K	0.06%	128
2023 Q4	$295K	Sell	1,785 -799	-31%	-$123K	0.08%	117
2023 Q3	$402K	Sell	2,584 -149	-5%	-$23.8K	0.12%	97
2023 Q2	$427K	Hold	2,733	–	–	0.12%	97
2023 Q1	$434K	Hold	2,733	–	–	0.14%	95
2022 Q4	$437K	Sell	2,733 -427	-14%	-$67.6K	0.16%	90
2022 Q3	$444K	Hold	3,160	–	–	0.17%	87
2022 Q2	$460K	Sell	3,160 -111	-3%	-$16.5K	0.16%	88
2022 Q1	$530K	Buy	+3,271	New	+$530K	0.15%	85

Other funds holding BBH

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.09B AUM 18.31% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.26B AUM 24.75% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $7.85B AUM 31.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Blue Fin Capital's BBH Position: Q2 2026 in Review

Blue Fin Capital held its VanEck Biotech ETF (BBH) position steady in Q2 2026 at 1,544 shares worth $314K. The position accounts for 0.05% of the portfolio, ranked #138.

Blue Fin Capital first reported a position in BBH in Q1 2022 and has held it in 18 quarters since. The position peaked at $530K in Q1 2022. 111 funds tracked by Wall St. Rank hold BBH as of Q2 2026.

Blue Fin Capital held 1,544 shares of VanEck Biotech ETF worth $314K as of Q2 2026.
Blue Fin Capital left its VanEck Biotech ETF share count unchanged in Q2 2026.
VanEck Biotech ETF made up 0.05% of Blue Fin Capital's portfolio in Q2 2026, its #138 holding.
Blue Fin Capital first reported a position in VanEck Biotech ETF in Q1 2022 and has held it in 18 quarters since.
Blue Fin Capital's VanEck Biotech ETF position peaked at $530K in Q1 2022.
111 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2026.

Based on Blue Fin Capital's 13F filing for Q2 2026, filed 4 Aug 2026.